Hiddo Lambers Heerspink
Rijksuniversiteit Groningen
H-index: 100
Europe-Netherlands
Top articles of Hiddo Lambers Heerspink
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial | Nephrology Dialysis Transplantation | Hiddo JL Heerspink Peter J Greasley Christine Ahlström Magnus Althage Jamie P Dwyer | 2024/3 |
Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial | Kidney International Reports | Akihiko Koshino Brendon L Neuen Megumi Oshima Tadashi Toyama Akinori Hara | 2024/2/1 |
Efficacy and safety of dapagliflozin in patients with chronic kidney disease across the spectrum of frailty | The Journals of Gerontology: Series A | Priya Vart Jawad H Butt Niels Jongs Meir Schechter Glenn M Chertow | 2024/2/1 |
Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gaps | Dominique van Mil Xavier GLV Pouwels Hiddo JL Heerspink Ron T Gansevoort | 2024/1 | |
Response to Comment on Curovic et al. Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover … | Diabetes Care | Viktor Rotbain Curovic Frederik Persson Niels Jongs Hiddo JL Heerspink | 2024/2/1 |
Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria | American Heart Journal | Hiddo JL Heerspink Michele Provenzano Priya Vart Niels Jongs Ricardo Correa-Rotter | 2024/2/15 |
WCN24-1550 ALDOSTERONE SYNTHASE INHIBITION WITH OR WITHOUT BACKGROUND SODIUM GLUCOSE COTRANSPORTER 2 INHIBITION IN CKD: A PHASE II CLINICAL TRIAL | Kidney International Reports | Katherine Tuttle Sibylle Hauske Shimoli V Shah Lisa Cronin Zhichao Sun | 2024/4/1 |
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes | Cardiovascular diabetology | Oliver Schnell Katharine Barnard-Kelly Tadej Battelino Antonio Ceriello Helena Elding Larsson | 2024/12 |
Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis | Circulation | Siddharth M Patel Yu Mi Kang KyungAh Im Brendon L Neuen Stefan D Anker | 2024/4/7 |
Inhibition of Interleukin-33 to Reduce Glomerular Endothelial Inflammation in Diabetic Kidney Disease | Kidney International Reports | Alexis Hofherr Elena Liarte Marin Barbara Musial Asha Seth Tim Slidel | 2024/3/18 |
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study | Kidney International Reports | Howard Trachtman Jai Radhakrishnan Michelle N Rheault Charles E Alpers Jonathan Barratt | 2024/1/28 |
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With … | Circulation | Brendon L Neuen Hiddo JL Heerspink Priya Vart Brian L Claggett Robert A Fletcher | 2024/2/6 |
WCN24-1766 EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY | Kidney International Reports | Hiddo JL Heerspink David C Wheeler Ricardo Correa-Rotter Jamie P Dwyer Anna Maria Langkilde | 2024/4/1 |
Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial | The Lancet Planetary Health | Zhiyan Zhang Hiddo JL Heerspink Glenn M Chertow Ricardo Correa-Rotter Antonio Gasparrini | 2024/4/1 |
Non-adherence to antidiabetic and cardiovascular medication as assessed by LC-MS/MS in urine and its association with kidney and cardiovascular outcomes in type 2 diabetes mellitus | Diabetologia | Sara Denicolò Vera Reinstadler Felix Keller Stefanie Thöni Susanne Eder | 2024/2/23 |
Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post‐hoc analysis of the ROTATE‐3 study | Diabetes, Obesity and Metabolism | Tom TGF Lieverse Maria J Puchades Udo DJ Mulder Michele Provenzano Guido Krenning | 2024/2 |
Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease | EClinicalMedicine | Xavier GLV Pouwels Dominique van Mil Lyanne M Kieneker Cornelis Boersma Ronald W van Etten | 2024/2/1 |
Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes | Vikas S Sridhar Christine P Limonte Per-Henrik Groop Hiddo JL Heerspink Richard E Pratley | 2024/1 | |
Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial | Journal of the American Society of Nephrology | Hiddo JL Heerspink Austin G Stack Robert Terkeltaub Niels Jongs Lesley A Inker | 2024/2/7 |
WCN24-1229 EFFECTS OF TREATMENT AND CLINICAL EVENTS ON QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A PRESPECIFIED ANALYSIS OF THE DAPA-CKD TRIAL | Kidney International Reports | Hiddo JL Heerspink Niels Jongs Ricardo Correa-Rotter Peter Rossing Robert D Toto | 2024/4/1 |
